127527-22-4

Basic information

• Product Name: Butanoyl chloride, 4-(dimethylamino)-
• Synonyms: 4-(dimethylamino)butanoyl chloride;4-dimethylamino-butyrylchloride;4-dimethylaminobutyric acid chloride;4-dimethylamino-butyryl chloride;4-(N,N-dimethylamino)butyrylchloride;4-dimethylamonobutanoyl chloride
• CAS NO: 127527-22-4
• Molecular Formula: C6H12ClNO
• Molecular Weight: 149.62
• Mol File: 127527-22-4.mol

Chemical Properties

• CAS DataBase Reference: Butanoyl chloride, 4-(dimethylamino)-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoyl chloride, 4-(dimethylamino)-(127527-22-4)
• EPA Substance Registry System: Butanoyl chloride, 4-(dimethylamino)-(127527-22-4)

Safety Data

• Hazardous Substances Data: 127527-22-4(Hazardous Substances Data)

Upstream product

• 69954-66-1 4-(dimethylamino)butyric acid hydrochloride 
• 693-11-8 4-dimethylamino-butyric acid 
• 79-37-8 oxalyl dichloride 
• 58-22-0 testosterone 
• 383865-57-4 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine 

Downstream Products

• 1383679-60-4 C₃₃H₄₁F₃N₈O₃ 
• 1595286-10-4 N-(4-((3-chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(dimethylamino)butanamide 
• 960062-04-8 C₅₃H₅₆N₁₄O₈S₆ 
• 1050672-70-2 4-dimethylaminobutanoic acid [4-(5-chloro-4-fluoro-3-methylphenylamino)-3-methyl-7-methoxyquinolin-6-yl]amide hydrochloride 

Relevant articles and documents

Discovery and optimization of phthalazinone derivatives as a new class of potent dengue virus inhibitors

Using a dengue replicon cell line-based screening, we identified 3-(dimethylamino)propyl(3-((4-(4-fluorophenyl)-1-oxophthalazin-2(1H)-yl)methyl)phenyl)carbamate (10a) as a potent DENV-2 inhibitor, with an IC50 value of 0.64 μM. A series of novel phthalazinone derivatives based on hit 10a were synthesized and evaluated for their in vitro anti-DENV activity and cytotoxicity. The subsequent SAR study and optimization led to the discovery of the most promising compound 14l, which displayed potent anti-DENV-2 activity, with low IC50 value against DENV-2 RNA replication of 0.13 μM and high selectivity (SI = 89.2) with acceptable pharmacokinetics profiles.

LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS

Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, G1, G2, and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Pyridazinone compound, preparation method thereof, pharmaceutical composition and application thereof

The invention relates to a pyridazinone compound shown as a formula I or an isomer thereof, or a pharmaceutically acceptable salt, ester, a prodrug or a solvate thereof, a preparation method thereof,a pharmaceutical composition and an application of the pharmaceutical composition for preparing a dengue virus inhibitor. The pyridazinone compound has a structure shown in the formula I. The compoundor the pharmaceutical composition thereof has anti-dengue virus activity and better selectivity, and can be used for preventing and/or treating dengue virus infection.

Investigation of the factors that dictate the preferred orientation of lexitropsins in the minor groove of DNA

Lexitropsins are small molecules that bind to the minor groove of DNA as antiparallel dimers in a specific orientation. These molecules have shown therapeutic potential in the treatment of several diseases; however, the development of these molecules to target particular genes requires revealing the factors that dictate their preferred orientation in the minor grooves, which to date have not been investigated. In this study, a distinct structure (thzC) was carefully designed as an analog of a well-characterized lexitropsin (thzA) to reveal the factors that dictate the preferred binding orientation. Comparative evaluations of the biophysical and molecular modeling results of both compounds showed that the position of the dimethylaminopropyl group and the orientation of the amide links of the ligand with respect to the 5′-3′-ends; dictate the preferred orientation of lexitropsins in the minor grooves. These findings could be useful in the design of novel lexitropsins to selectively target specific genes.

Identification of indole inhibitors of human hematopoietic prostaglandin D2 synthase (hH-PGDS)

Abstract Human H-PGDS has shown promise as a potential target for anti-allergic and anti-inflammatory drugs. Here we describe the discovery of a novel class of indole inhibitors, identified through focused screening of 42,000 compounds and evaluated using a series of hit validation assays that included fluorescence polarization binding, 1D NMR, ITC and chromogenic enzymatic assays. Compounds with low nanomolar potency, favorable physico-chemical properties and inhibitory activity in human mast cells have been identified. In addition, our studies suggest that the active site of hH-PGDS can accommodate larger structural diversity than previously thought, such as the introduction of polar groups in the inner part of the binding pocket.

Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design

Mutations in the catalytic domain at the gatekeeper position represent the most prominent drug-resistant variants of kinases and significantly impair the efficacy of targeted cancer therapies. Understanding the mechanisms of drug resistance at the molecular and atomic levels will aid in the design and development of inhibitors that have the potential to overcome these resistance mutations. Herein, by introducing adaptive elements into the inhibitor core structure, we undertake the structure-based development of type II hybrid inhibitors to overcome gatekeeper drug-resistant mutations in cSrc-T338M, as well as clinically relevant tyrosine kinase KIT-T670I and Abl-T315I variants, as essential targets in gastrointestinal stromal tumors (GISTs) and chronic myelogenous leukemia (CML). Using protein X-ray crystallography, we confirm the anticipated binding mode in cSrc, which proved to be essential for overcoming the respective resistances. More importantly, the novel compounds effectively inhibit clinically relevant gatekeeper mutants of KIT and Abl in biochemical and cellular studies.

Benzothiazole derivatives with activity as adenosine receptor ligands

The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.

Testosterone prodrugs for improved drug delivery

Compositions and methods are provided for enhanced transdermal electrotransport of 17-hydroxy sterol compounds, including testosterone. The parent sterols are modified at the 17-hydroxy position by covalent attachment of a charged chemical modifier. The chemical modifier provides the parent sterol with enhanced transport properties and is hydrolyzed under physiological conditions to release the active parent compound. The composition comprises a 17-hydroxy sterol/chemical modifier complex, more generally represented by the formula (sterol--O--)C(O)--R--N(R1)(R2)(R3)+. The portion of the complex derived from the chemical modifier is indicated by "C(O)--R--N(R1)(R2)(R3)+ ", where N(R1)(R2)(R3)+ represents a quaternary ammonium group and R1, R2, and R3 are independently selected from the group consisting of lower alkyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroalkyl, and heteroarylalkyl; or R1 and R2 together with the nitrogen to which they are attached form a substituted heterocycle and R3 is lower alkyl, and R is a linking moiety, linking the (sterol--O)--C(O)-- to the nitrogen atom.